Tralokinumab
Last Updated: 2026-09-17
Author(s): -
Reviewer(s): -
Cite
Permalink
Adtralza® Tralokinumab
Leo Pharmaceuticals
Human monoclonal IgG4 antibody that binds to and neutralises IL-13 or IL-4/13 receptors.
Indicated for adult patients with moderate to severe atopic dermatitis, where treatment with prescription topical medicines does not provide adequate control of the condition or is not recommended.
No
Treatment of adult patients (aged 18 years and over) with severe atopic dermatitis (IGA 4 [on the IGA scale of 0–4] or SCORAD >50 or EASI ≥ 21.1) following an inadequate response (or contraindication or discontinuation due to adverse effects) to intensive topical therapies (topical corticosteroids and/or calcineurin inhibitors) and phototherapy (where available and indicated) and to systemic treatment with a conventional immunosuppressant (excluding systemic corticosteroids) for 1 month.
Pre-filled syringe
No blood tests required before starting treatment. Optional: complete blood count, liver function tests, screening for HBV and HCV.
Optional for home administration: training of the patient before using auto-injectors; first dose to be administered under medical supervision.
Not necessary, clinical monitoring only.
Every 3 months
s.c.
Initial dose of 600 mg (four subcutaneous injections of 150 mg each), followed by 300 mg subcutaneously every two weeks, or, at the prescribing doctor’s discretion, every four weeks once the skin has healed completely or almost completely.
Approx. 2–4 weeks.
If there is an inadequate response after 16 weeks, adjust the treatment.
Adtralza® 300 mg: every 2 weeks: approx. 14,100; every 4 weeks in the first year when switching from a 2-week to a 4-week dosing schedule from week 16 onwards: approx. 9,590; every 4 weeks in the second year: approx. 6,770.
Helminthiasis under treatment and lack of response to treatment, hypersensitivity reaction.
| ECZTRA 3 (combined with TCS): Week 16 at 300 mg Adtralza | |
| EASI 75 | 56 per cent |
| Itch NRS (≥4-point improvement): | 45.4 per cent |
| SCORAD 50: | 61.1 per cent |
| DLQI (≥4-point improvement) | 83.5 per cent |
ADA in 4.6% of patients, persistent ADA in 0.9%, neutralising antibodies in 1%.
Hypersensitivity to the active substance or any of the excipients listed in the composition; breastfeeding and pregnancy (insufficient data; therefore, an individual risk-benefit assessment is required); no data available on patients with suicidal thoughts or behaviour.
(Allergic) conjunctivitis, hypersensitivity reaction, upper respiratory tract infections, eosinophilia, keratitis, reactions at the injection site.
Insufficient data, individual risk assessment.
Insufficient data, individual risk assessment.
Insufficient data, individual risk assessment.
No live vaccines (at least 30 days before and after the end of treatment).
Screening not recommended by the manufacturer.
Insufficient data
This website uses cookies!
We use cookies to tailor our content to your needs and continuously improve our website. You can decide which cookies you want to allow. Detailed information about the cookies we use can be found in our Privacy Policy and Cookie Settings. You can withdraw your consent at any time.
